Análisis

While a weak won usually boosts exporters, pharma and biotech firms see mixed effects as foreign revenue growth is offset by rising foreign‑currency costs for raw materials, debt and liabilities.

Korean Aebot and Samjin Pharma have sharply increased the supply price of the pediatric and adult antidiarrheal Hydrasexan due to raw‑material costs and exchange‑rate shifts.